Imperial Innovations

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Resolver is an independent online resolution service that connects consumers directly with businesses to address customer service issues efficiently. The platform facilitates communication and provides a streamlined process for resolving disputes, ensuring that consumers can effectively voice their concerns while businesses can retain their customers. Resolver offers a fully online, end-to-end arbitration and dispute resolution system, which is both fast and cost-effective. Additionally, the platform delivers value-added services to businesses by enhancing the issue-resolution process and providing real-time consumer feedback insights through advanced AI technology. This comprehensive approach allows consumers to receive guidance throughout the complaint process, while enterprises can transform their handling of customer complaints.

ThisWay Global Limited, established in 2014, is a UK-based hiring solutions provider, headquartered in Cambridge with a business office in Westminster. It assists businesses in reaching passive and active candidates, offers HR functions for startups and SMEs, and manages large-scale recruitment. Additionally, it caters to associations and organizations in fields like education, arts, and charities, helping them find suitable opportunities. ThisWay also aids recruiters in managing numerous CVs and jobs, and helps specialist recruiters find hires. Meanwhile, ThisWay Global LLC, incorporated in 2016 and based in Austin, Texas, develops recruitment solutions using AI and blockchain technology. Its flagship product, AI4Jobs, offers an applicant matching engine for talent acquisition, providing 20 times more efficient and accurate sourcing of qualified talent, and enhancing diversity and inclusion.

Concirrus Ltd., established in 2011 and headquartered in London, operates a cloud-based platform that connects diverse data sources and devices, enabling clients to extract and manage various data types. The company specializes in transforming businesses by leveraging its technology to collect, organize, and analyze information from connected products and machines. Concirrus offers custom solutions, including consultancy, implementation, and support services, as well as a portfolio of pre-built applications in areas such as asset security, fleet management, and smart energy. Its incident monitoring center responds to alarms for theft recovery and high-value asset security. Serving global clients in sectors like healthcare, security, mining, and insurance, Concirrus has a strategic partnership with PressurePro. Notably, the company's AI-driven marine insurance platform, Quest, empowers underwriting teams to make data-driven decisions, improving loss ratios and reducing operational expenses.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Abingdon Health Plc is a technology-enabled lateral flow diagnostics company based in York, United Kingdom. Founded in 2008, the company specializes in the development, manufacturing, and marketing of rapid diagnostic tests for medical use, catering to a global clientele. Its flagship product, the AbC-19 Rapid Test, is a COVID-19 neutralizing antibody test. In addition to COVID-19 testing, Abingdon Health offers various other diagnostic solutions, including tests for self-test HIV, equine infections, and human fertility. The company's operations are structured into several segments, including Contract Development for third-party projects, Contract Manufacturing for manufacturing activities, and Product Sales encompassing a range of diagnostic products. Abingdon Health's focus on innovation and technology positions it as a key player in the field of rapid and near-patient medical diagnostics.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Inflowmatix Limited is a technology company based in London that specializes in designing and implementing electronic systems for water utilities globally. Founded in 2015 as a spin-out from Imperial College London's InfraSense Labs, Inflowmatix focuses on providing water flow and system health analytics to enhance the operation of water supply networks. Their innovative solutions continuously monitor and analyze fluid dynamics, enabling operators to optimize performance, manage leakage, and improve energy efficiency. By capturing high-frequency pressure data and applying advanced modeling techniques, Inflowmatix helps water companies gain insights into their operations, extend the life of aging infrastructure, and address challenges posed by increasing population demands and climate change. The company’s technology aims to deliver compelling returns on investment while supporting water utilities in maintaining high-quality service within cost constraints.

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Aqdot Limited, founded in 2012 and based in Cambridge, United Kingdom, specializes in manufacturing smart microcapsules through innovative fabrication technology. Its unique approach combines emulsion technology and supramolecular chemistry to simplify the microencapsulation process using a one-step shrink-wrap method. This technology is energy- and raw material-efficient, contributing to reduced energy consumption and waste. Aqdot's microcapsules have versatile applications across various industries, including home care, beauty, pet care, food, and agrochemicals. The encapsulation technology enables the protection and controlled release of active ingredients, making it suitable for products like laundry detergents, fertilizers, and odor-capturing technologies. With a focus on customization, Aqdot serves a multi-billion-dollar market, addressing the growing demand for effective and sustainable encapsulation solutions.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

SAM Labs Limited is an education technology company based in London that specializes in providing innovative teaching resources for educators. Founded in 2014, the company offers a range of products, including wireless electronic blocks, buttons, sensors, motors, and sliders, which can be connected and programmed using their SAM Space software application. This platform enables students to visualize and code the blocks in an intuitive manner, fostering an engaging STEAM learning experience. SAM Labs provides curriculum-based lesson plans and hands-on support for educators, making coding and computational skills accessible and interactive. Their offerings include course kits and electronic products available for purchase online, allowing educators to create a dynamic classroom environment where students can design, write, and debug their own programs, while learning essential concepts such as sequencing, selection, and logical reasoning.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Silicon Microgravity Limited specializes in the development of advanced sensor devices tailored for the oil and gas sector. Founded in 2014 as a spin-out from Cambridge University, the company leverages sensor technology originally developed through a collaboration with BP. This technology enables the recording of gravity data at high sensitivities and seismic data at ultra-low frequencies, significantly enhancing the management of oil and gas reservoirs. By using microelectromechanical system sensors, Silicon Microgravity transforms the measurement of densities deep within reservoirs from boreholes. Additionally, its technology finds applications in navigation, guidance, and stabilization for various intelligent systems across commercial, industrial, and military sectors. The innovations provided by Silicon Microgravity aim to improve efficiency and reduce costs for clients while supporting their social, safety, and environmental objectives.

Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and based in Abingdon-on-Thames, United Kingdom, the company focuses on creating optical components that enhance the augmented reality experience. Their patented technology utilizes waveguide hologram physics and photonic crystals, allowing for lightweight, high field-of-view displays in full RGB color. By employing thin transparent substrates embedded with nanostructures, WaveOptics' devices manipulate light to generate images without the need for bulkier components traditionally used in AR systems. The company has established strategic partnerships with industry leaders such as Compal, Wistron, and Plessey to further its mission in the augmented reality market.

Telectic they provide AI capability to read the web and uncover hard to find B2B prospects, map emerging sectors, segment accounts and monitor companies on particular topics or signals. They have developed a crawler that understands the content from the web, reading company websites, news, social media, academic, official, and other sources.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, established in 2013. It specializes in the development of innovative purification technologies aimed at enhancing the manufacturing of industrial biomolecules. The company has created FibroSelect, a nanofiber-based platform purification technology that addresses limitations associated with traditional packed bed chromatography systems and chromatography membranes. This technology is designed to provide consistent purification performance across various scales, making it particularly suitable for the purification of macromolecular biotherapeutics such as gene therapies, viral vectors, and fusion proteins. By improving purification efficiencies, Puridify enables the production of cost-effective biomolecule products, supporting advancements in the biopharmaceutical sector. As of late 2017, Puridify operates as a subsidiary of GE Healthcare Limited.

Oxford Biotrans Limited is a company based in Abingdon, United Kingdom, that focuses on the development and commercialization of high-value chemical compounds through enzyme technology. Established in 2013, it leverages patented cytochrome P450 enzyme technology to create products such as Nootkatone, a naturally derived flavor and fragrance from Valencene, a citrus extract. The company aims to introduce innovative enzymatic routes for producing specialty chemicals, with initial offerings centered on flavors and fragrances. Additionally, the technology has broader applications in the production of pheromones, pharmaceuticals, and other specialty chemicals. With over 15 years of research backing its initiatives, Oxford Biotrans is committed to providing environmentally friendly ingredients that minimize chemical waste and energy consumption.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.

Abingdon Health Plc is a technology-enabled lateral flow diagnostics company based in York, United Kingdom. Founded in 2008, the company specializes in the development, manufacturing, and marketing of rapid diagnostic tests for medical use, catering to a global clientele. Its flagship product, the AbC-19 Rapid Test, is a COVID-19 neutralizing antibody test. In addition to COVID-19 testing, Abingdon Health offers various other diagnostic solutions, including tests for self-test HIV, equine infections, and human fertility. The company's operations are structured into several segments, including Contract Development for third-party projects, Contract Manufacturing for manufacturing activities, and Product Sales encompassing a range of diagnostic products. Abingdon Health's focus on innovation and technology positions it as a key player in the field of rapid and near-patient medical diagnostics.

Auspherix Pty Ltd. is an early-stage anti-infectives company based in Stevenage, United Kingdom, focused on the discovery and development of organogold-based antibiotics aimed at treating serious and challenging infections that may be life-threatening. Established in 2013, the company is working to advance its novel antibiotic candidates through pre-clinical and clinical development stages. To facilitate this progress, Auspherix is seeking additional investment and industry partnerships to support the broad-spectrum application of its innovative therapies.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

Cortexica Vision Systems Ltd is a London-based company that specializes in vision-based analytics and artificial intelligence solutions tailored for various industries, including retail, media, manufacturing, and pharmaceuticals. Established in 2008, the company offers advanced visual search and image recognition technologies that enhance the digital shopping experience by enabling product discovery and personalization for e-commerce. Its AI-driven tools automate retail operations, improving efficiency and reducing costs. Cortexica also provides a range of video solutions for real-time monitoring and compliance, such as AI-PPE compliance detection and CCTV systems that predict and identify unusual behaviors. Additionally, the company offers edge solutions that facilitate local processing and video analysis. Originating from research at the Bioengineering Department of Imperial College London, Cortexica is designed to adapt to specific client needs, ensuring effective integration and optimal return on investment. It operates as a subsidiary of Zebra Technologies Corporation.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Lontra Limited, established in 2004 and headquartered in Napton-on-the-Hill, UK, specializes in the development and manufacturing of innovative air and gas compressors. The company's flagship product, the Blade Compressor, is a patented, rotary device that offers up to a third more efficiency than traditional compressors, reducing energy consumption and enhancing reliability. Lontra serves a diverse range of industries, including automotive, wastewater treatment, power generation, and manufacturing, with customers in the UK and internationally. The company's success is underpinned by strategic partnerships with leading industry players and recognition from prominent organizations such as Innovate UK and the Institution of Mechanical Engineers.

Cortexica Vision Systems Ltd is a London-based company that specializes in vision-based analytics and artificial intelligence solutions tailored for various industries, including retail, media, manufacturing, and pharmaceuticals. Established in 2008, the company offers advanced visual search and image recognition technologies that enhance the digital shopping experience by enabling product discovery and personalization for e-commerce. Its AI-driven tools automate retail operations, improving efficiency and reducing costs. Cortexica also provides a range of video solutions for real-time monitoring and compliance, such as AI-PPE compliance detection and CCTV systems that predict and identify unusual behaviors. Additionally, the company offers edge solutions that facilitate local processing and video analysis. Originating from research at the Bioengineering Department of Imperial College London, Cortexica is designed to adapt to specific client needs, ensuring effective integration and optimal return on investment. It operates as a subsidiary of Zebra Technologies Corporation.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, established in 2013. It specializes in the development of innovative purification technologies aimed at enhancing the manufacturing of industrial biomolecules. The company has created FibroSelect, a nanofiber-based platform purification technology that addresses limitations associated with traditional packed bed chromatography systems and chromatography membranes. This technology is designed to provide consistent purification performance across various scales, making it particularly suitable for the purification of macromolecular biotherapeutics such as gene therapies, viral vectors, and fusion proteins. By improving purification efficiencies, Puridify enables the production of cost-effective biomolecule products, supporting advancements in the biopharmaceutical sector. As of late 2017, Puridify operates as a subsidiary of GE Healthcare Limited.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Cambridge Communication Systems Limited, based in Cambridge, United Kingdom, specializes in designing and developing self-organizing wireless backhaul solutions. Founded in 2010, the company focuses on providing cost-effective connectivity for various applications, including small cells, Wi-Fi, CCTV, and smart city infrastructure. Its flagship product, Metnet, features self-organizing 5G microwave backhauls and is complemented by the Metnet SON Multipoint solution, which operates in the 24/26/28GHz frequency range. The company's technology enables intelligent, self-optimizing, and self-healing mesh networks, allowing network operators to extend fiber connectivity effectively. This approach facilitates the development of hybrid fiber-wireless networks that cater to diverse environments, from urban to rural areas, and supports a wide range of users from residential to enterprise settings.

Impression Technologies Limited, established in 2012 and based in London, specializes in the marketing and commercialization of its innovative Hot Form Quench (HFQ) technology. This technology allows for the efficient formation of aluminum panels into complex shapes, catering to various engineering needs. The company offers a comprehensive service that spans from concept development to production, providing the necessary expertise to support clients in utilizing HFQ technology effectively. Impression Technologies operates a fully equipped facility in Coventry, UK, where it conducts in-house prototyping and production runs to meet the demands of its HFQ customers and partners.

Semetric, founded in 2008 by Gregory Mead, Marie-Alicia Chang, and Matthew Jeffery, specializes in providing data-driven insights and analytics for the entertainment industry. The company's offerings include analytics, discovery, recommendations, and targeting services, aimed at enhancing business decisions within the sector. The leadership team features industry veterans such as Jameel Syed, the Chief Technical Officer with a background in life sciences data and business analytics, and Dr. Jeremy Silver, the Executive Chairman, who has held significant roles in software and media companies. Additionally, Daniel Savage, the Executive Vice President for Musicmetric North America, brings experience from various major record labels. Through its innovative solutions, Semetric supports clients in navigating and leveraging data for improved performance in entertainment.

Musicmetric provides analytics and trend forecasting tools tailored for the music industry, utilizing machine learning algorithms to assess online engagement and deliver actionable insights. The company's software is designed to analyze marketing performance, enhancing campaign efficiency and targeting accuracy. It offers predictive trend forecasting for artists, genres, and sales across various sectors, including mainstream labels, indie artists, and unsigned musicians. By processing vast amounts of raw text data daily, Musicmetric conducts data mining and classification analysis to fuel its software solutions. Additionally, the company is developing a suite of free widgets and an API to enable third parties to create applications leveraging its data. Its clientele includes record labels, A&R representatives, managers, promoters, and marketing agencies.

Acunu Analytics specializes in providing a platform for low-latency, continuous analytics on big data, enabling real-time insights across various industries such as manufacturing, telecommunications, media, and financial services. The company's offerings include dashboards and embedded applications designed for monitoring and controlling complex environments where high-velocity data is prevalent. Central to Acunu's technology is the Cassandra NoSQL database, and the company actively contributes to its development by sharing innovations with the wider community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford, Acunu operates offices in London and California, and is supported by prominent venture capital firms in Europe.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Abingdon Health Plc is a technology-enabled lateral flow diagnostics company based in York, United Kingdom. Founded in 2008, the company specializes in the development, manufacturing, and marketing of rapid diagnostic tests for medical use, catering to a global clientele. Its flagship product, the AbC-19 Rapid Test, is a COVID-19 neutralizing antibody test. In addition to COVID-19 testing, Abingdon Health offers various other diagnostic solutions, including tests for self-test HIV, equine infections, and human fertility. The company's operations are structured into several segments, including Contract Development for third-party projects, Contract Manufacturing for manufacturing activities, and Product Sales encompassing a range of diagnostic products. Abingdon Health's focus on innovation and technology positions it as a key player in the field of rapid and near-patient medical diagnostics.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

Cambridge Communication Systems Limited, based in Cambridge, United Kingdom, specializes in designing and developing self-organizing wireless backhaul solutions. Founded in 2010, the company focuses on providing cost-effective connectivity for various applications, including small cells, Wi-Fi, CCTV, and smart city infrastructure. Its flagship product, Metnet, features self-organizing 5G microwave backhauls and is complemented by the Metnet SON Multipoint solution, which operates in the 24/26/28GHz frequency range. The company's technology enables intelligent, self-optimizing, and self-healing mesh networks, allowing network operators to extend fiber connectivity effectively. This approach facilitates the development of hybrid fiber-wireless networks that cater to diverse environments, from urban to rural areas, and supports a wide range of users from residential to enterprise settings.

Epsilon-3 Bio Ltd. is a preclinical stage company with investment from Index Ventures, Novo Ventures and Imperial Innovations. The company is focused on the efficient development of first in class drug candidates stimulating safe removal of cellular debris. Such agents are expected to provide a useful treatment for a wide range of diseases including inflammation and autoimmunity, neurodegeneration, fibrosis and cancer.

TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

Chirp is dedicated to simplifying connectivity through the use of sound. The company has developed machine-to-machine communication software that allows devices equipped with loudspeakers or microphones to exchange data via inaudible sound waves. This innovative approach is supported by extensive research and a skilled engineering team, enabling the seamless interconnection of millions of devices in a scalable and cost-effective manner. By enhancing the end-user experience and adding value to existing hardware, Chirp positions itself as a leader in sound-based data transmission technology.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Stanmore Implants Worldwide Ltd., established in 1949, specializes in designing and manufacturing orthopedic implant systems for both juvenile and adult patients. The company focuses on orthopedic oncology, complex primary and revision cases in the upper limb, lower limb, and pelvis. Its product portfolio includes modular implant systems like METS, patient-specific implants, and extendible prostheses for limb-sparing and complex joint replacement. Stanmore Implants also offers a custom implant service and has a strategic partnership with WebOps LLC. The company, headquartered in Elstree, UK, operates as a subsidiary of Stryker Corporation.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Novacem Limited, based in London, UK, specializes in the development of innovative cement solutions that leverage magnesium oxide. The company's primary focus is on creating carbon-negative cement systems that have the potential to significantly reduce the environmental impact of the cement industry, traditionally known for its high carbon dioxide emissions. By utilizing magnesium oxide and hydrated magnesium carbonates, Novacem aims to transform cement production into a process that can absorb CO2, thereby contributing to more sustainable construction practices and addressing climate change challenges.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Novacem Limited, based in London, UK, specializes in the development of innovative cement solutions that leverage magnesium oxide. The company's primary focus is on creating carbon-negative cement systems that have the potential to significantly reduce the environmental impact of the cement industry, traditionally known for its high carbon dioxide emissions. By utilizing magnesium oxide and hydrated magnesium carbonates, Novacem aims to transform cement production into a process that can absorb CO2, thereby contributing to more sustainable construction practices and addressing climate change challenges.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Evince Technology is a UK-based start-up focused on developing innovative electron devices for various industries, including metrology, healthcare, communications, and advanced manufacturing. The company has created a new type of solid-state switch that aims to transform the high-frequency electronics sector. Its technology leverages synthetic diamonds to enhance the performance of these devices through thermionic valves, which utilize the exceptional thermal and electronic properties of diamonds. This advancement positions Evince as a key player in providing efficient solutions for effective electrical energy control, catering to the needs of developers and manufacturing partners.

Spiral Gateway is a fabless semiconductor chip vendor with products that are designed to enhance flexibility and performance in the Image Signal Processing (ISP) market. The company was formed in 2004 as a spinout from the University of Edinburgh and holds exclusive rights to RICA (Reconfigurable Instruction Cell Architecture), a novel processing architecture and associated tool chain. This technology has the potential to achieve cost & performance points for existing signal processing functions, directly comparable with fixed function custom hardware, whilst offering the significant additional benefit of high degrees of flexibility through software programmability.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Molecular Vision is an optical detection company based in London, United Kingdom, founded in 2001. It specializes in developing and manufacturing innovative diagnostic testing solutions, particularly through its platform technology that integrates low-cost organic light-emitting diodes and organic photodetectors. The company focuses on creating instrument-free, disposable point-of-care devices capable of performing multiple diagnostic tests from a single sample, yielding both quantitative and qualitative results. These portable devices are designed for various applications, including medical diagnostics, veterinary testing, environmental monitoring, food and plant testing, and enhancing homeland security measures.

NanoBioDesign Limited (NBD) was formed in 2001 and is a spinout company from Imperial College London. The company has acquired the exclusive rights to four patents emanating from the research of Professor Gianfranco Gilardi and his group. Professor Gilardi has been active in the field of biological sensor research for 10 years, focussing upon human and bacterial P450’s.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Southside Thermal Sciences is developing an integrated system for turbine engines consisting of thermal barrier coatings (TBC) and the instruments required to make use of them. The TBC technology, which is patent-protected in the USA and Europe, has been developed for use on high temperature turbine blades, as used in gas-turbine power generators and aircraft engines. When illuminated by UV light the coatings provide accurate temperature readings leading to savings in operating costs and greater efficiency.

InforSense, Ltd. specializes in enterprise business intelligence and reporting software, focusing on data integration, automation, and visualization. Its core offerings include the InforSense Platform, which provides tools for predictive insights, and various advanced analytics and reporting technologies, such as VisualSense and TextSense. The company also develops Life Science Applications, including ClinicalSense for clinical research, GenSense for high-throughput genotyping analysis, and BioSense for bioinformatics solutions. Additionally, InforSense offers business intelligence products for sectors like asset management and operational risk. The company serves diverse industries, including pharmaceutical, healthcare, and financial services, and operates in the United Kingdom, United States, Germany, and Japan. Founded in 1999 and headquartered in London, InforSense is a subsidiary of ID Business Solutions Ltd.

Lontra Limited, established in 2004 and headquartered in Napton-on-the-Hill, UK, specializes in the development and manufacturing of innovative air and gas compressors. The company's flagship product, the Blade Compressor, is a patented, rotary device that offers up to a third more efficiency than traditional compressors, reducing energy consumption and enhancing reliability. Lontra serves a diverse range of industries, including automotive, wastewater treatment, power generation, and manufacturing, with customers in the UK and internationally. The company's success is underpinned by strategic partnerships with leading industry players and recognition from prominent organizations such as Innovate UK and the Institution of Mechanical Engineers.

Midaz Lasers manufactures high power diode-pumped solid state laser products for micromachining applications.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Vivant is a digital media and technology platform that focuses on fashion and lifestyle content, offering users trend reports, shopping guides, and news related to celebrity styles. Founded in 2008 by a team that includes Ari S. Goldberg and Maverick Carter, the platform serves as a space for women to express their individual style and connects them with brands to enhance advertising effectiveness. By fostering engagement among users who prioritize their appearance and well-being, Vivant aims to create a supportive community that celebrates personal style.

Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.